Antiangiogenic agent SU6668 suppresses the tumor growth of xenografted A-431 cells

Takeshi Nakamura, Soji Ozawa, Yuukou Kitagawa, Masakazu Ueda, Tetsuro Kubota, Masaki Kitajima

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

SU6668 is an antiangiogenic agent that acts as a tyrosine kinase inhibitor for the vascular endothelial growth factor (VEGF) receptor. We treated xenografted A-431, a human squamous cell carcinoma cell line, with SU6668 to investigate the efficacy of tumor dormant therapy using angiogenesis inhibitors for patients with squamous cell carcinoma. A-431 cells were transplanted into severe combined immunodeficient (SCID) mice. The treatment group was given SU6668 at a dose of 200 mg/kg orally twice a day for 3 weeks; the control group was given only the vehicle in the same manner and intervals. SU6668 suppressed tumor growth of A-431 cells in the xenograft model. Furthermore, tumor volume and the number of vessels were significantly reduced in the treatment group compared with those of the control. No significant differences in body weight were found between the treatment and control groups, and no toxic reactions occurred during the experiment. We concluded that this agent was safe, efficient and potentially useful for the treatment of patients with squamous cell carcinoma.

Original languageEnglish
Pages (from-to)79-83
Number of pages5
JournalOncology Reports
Volume15
Issue number1
Publication statusPublished - 2006 Jan

Fingerprint

Angiogenesis Inhibitors
Growth
Squamous Cell Carcinoma
Neoplasms
Therapeutics
Control Groups
Vascular Endothelial Growth Factor Receptor
SCID Mice
Poisons
Tumor Burden
Heterografts
Protein-Tyrosine Kinases
Body Weight
orantinib
Cell Line

Keywords

  • A-431
  • Angiogenesis
  • Squamous cell carcinoma
  • SU6668
  • Xenograft model

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nakamura, T., Ozawa, S., Kitagawa, Y., Ueda, M., Kubota, T., & Kitajima, M. (2006). Antiangiogenic agent SU6668 suppresses the tumor growth of xenografted A-431 cells. Oncology Reports, 15(1), 79-83.

Antiangiogenic agent SU6668 suppresses the tumor growth of xenografted A-431 cells. / Nakamura, Takeshi; Ozawa, Soji; Kitagawa, Yuukou; Ueda, Masakazu; Kubota, Tetsuro; Kitajima, Masaki.

In: Oncology Reports, Vol. 15, No. 1, 01.2006, p. 79-83.

Research output: Contribution to journalArticle

Nakamura, T, Ozawa, S, Kitagawa, Y, Ueda, M, Kubota, T & Kitajima, M 2006, 'Antiangiogenic agent SU6668 suppresses the tumor growth of xenografted A-431 cells', Oncology Reports, vol. 15, no. 1, pp. 79-83.
Nakamura T, Ozawa S, Kitagawa Y, Ueda M, Kubota T, Kitajima M. Antiangiogenic agent SU6668 suppresses the tumor growth of xenografted A-431 cells. Oncology Reports. 2006 Jan;15(1):79-83.
Nakamura, Takeshi ; Ozawa, Soji ; Kitagawa, Yuukou ; Ueda, Masakazu ; Kubota, Tetsuro ; Kitajima, Masaki. / Antiangiogenic agent SU6668 suppresses the tumor growth of xenografted A-431 cells. In: Oncology Reports. 2006 ; Vol. 15, No. 1. pp. 79-83.
@article{3a654dcbfcea4d20a97d8997a26afc1a,
title = "Antiangiogenic agent SU6668 suppresses the tumor growth of xenografted A-431 cells",
abstract = "SU6668 is an antiangiogenic agent that acts as a tyrosine kinase inhibitor for the vascular endothelial growth factor (VEGF) receptor. We treated xenografted A-431, a human squamous cell carcinoma cell line, with SU6668 to investigate the efficacy of tumor dormant therapy using angiogenesis inhibitors for patients with squamous cell carcinoma. A-431 cells were transplanted into severe combined immunodeficient (SCID) mice. The treatment group was given SU6668 at a dose of 200 mg/kg orally twice a day for 3 weeks; the control group was given only the vehicle in the same manner and intervals. SU6668 suppressed tumor growth of A-431 cells in the xenograft model. Furthermore, tumor volume and the number of vessels were significantly reduced in the treatment group compared with those of the control. No significant differences in body weight were found between the treatment and control groups, and no toxic reactions occurred during the experiment. We concluded that this agent was safe, efficient and potentially useful for the treatment of patients with squamous cell carcinoma.",
keywords = "A-431, Angiogenesis, Squamous cell carcinoma, SU6668, Xenograft model",
author = "Takeshi Nakamura and Soji Ozawa and Yuukou Kitagawa and Masakazu Ueda and Tetsuro Kubota and Masaki Kitajima",
year = "2006",
month = "1",
language = "English",
volume = "15",
pages = "79--83",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Antiangiogenic agent SU6668 suppresses the tumor growth of xenografted A-431 cells

AU - Nakamura, Takeshi

AU - Ozawa, Soji

AU - Kitagawa, Yuukou

AU - Ueda, Masakazu

AU - Kubota, Tetsuro

AU - Kitajima, Masaki

PY - 2006/1

Y1 - 2006/1

N2 - SU6668 is an antiangiogenic agent that acts as a tyrosine kinase inhibitor for the vascular endothelial growth factor (VEGF) receptor. We treated xenografted A-431, a human squamous cell carcinoma cell line, with SU6668 to investigate the efficacy of tumor dormant therapy using angiogenesis inhibitors for patients with squamous cell carcinoma. A-431 cells were transplanted into severe combined immunodeficient (SCID) mice. The treatment group was given SU6668 at a dose of 200 mg/kg orally twice a day for 3 weeks; the control group was given only the vehicle in the same manner and intervals. SU6668 suppressed tumor growth of A-431 cells in the xenograft model. Furthermore, tumor volume and the number of vessels were significantly reduced in the treatment group compared with those of the control. No significant differences in body weight were found between the treatment and control groups, and no toxic reactions occurred during the experiment. We concluded that this agent was safe, efficient and potentially useful for the treatment of patients with squamous cell carcinoma.

AB - SU6668 is an antiangiogenic agent that acts as a tyrosine kinase inhibitor for the vascular endothelial growth factor (VEGF) receptor. We treated xenografted A-431, a human squamous cell carcinoma cell line, with SU6668 to investigate the efficacy of tumor dormant therapy using angiogenesis inhibitors for patients with squamous cell carcinoma. A-431 cells were transplanted into severe combined immunodeficient (SCID) mice. The treatment group was given SU6668 at a dose of 200 mg/kg orally twice a day for 3 weeks; the control group was given only the vehicle in the same manner and intervals. SU6668 suppressed tumor growth of A-431 cells in the xenograft model. Furthermore, tumor volume and the number of vessels were significantly reduced in the treatment group compared with those of the control. No significant differences in body weight were found between the treatment and control groups, and no toxic reactions occurred during the experiment. We concluded that this agent was safe, efficient and potentially useful for the treatment of patients with squamous cell carcinoma.

KW - A-431

KW - Angiogenesis

KW - Squamous cell carcinoma

KW - SU6668

KW - Xenograft model

UR - http://www.scopus.com/inward/record.url?scp=33644873854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644873854&partnerID=8YFLogxK

M3 - Article

C2 - 16328037

AN - SCOPUS:33644873854

VL - 15

SP - 79

EP - 83

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1

ER -